肿瘤的鉴定手段医学课检测和治疗(中英文）幻灯片.pptVIP

Diagnostic Tools in CancerDetection and Treatment(肿瘤的鉴定手段- 检测和治疗-); (1979年到2002年，世界总的 经费消耗和保健系统的关系图);Annual increase in costs for medical drugs is 10-12% (Sweden) (瑞典每年的医药增加10-12%);The increase in costs for diagnostic procedures is even higher.;DIAGNOSTIC TOOLS (鉴定手段);X-RAY (X-光) ULTRASOUND (B-超) CT (肿瘤细胞电脑图) MRI (赫磁共振) SCINTIGRAPHY (同位素示踪成像);X-RAY (X-光) ;ULTRASOUND (B-超);Computed Tomography (CT)(肿瘤细胞电脑图);Magnetic Resonance (MRI) (赫磁共振);Surgical Biopsy (外科手术样品);+ Simple (血清样品) + No risks (不伤害组织) + Repetable (可重复性) + Dynamic (无动力学观察) + Qualitative information possible (可能定量) + Good health economy (用费少) + Screening possible ( 筛选 的可能性) Diagnosis dependent specificity (肿瘤的鉴定取得决于其特异性) Still scanty prospective data (仍是需要多的数据做统计分析) ; (1979年到2002年，世界总的 经费消耗和保健系统的关系图);Costs For Assessment of Treatment Effect (评估治疗效果的费用);Possible Use of Serum Tumour Markers (血清标志物应用的可能性);S-TK1;0.00;A serum tumour marker that is not sensitive or specific enough for screening and detection of MRD may nevertheless be extremely useful and cost effective by reducing the costs for response evaluation and by reducing the costs for ineffective cytotoxic and endocrine treatment (尽管一个肿瘤标志物不灵敏或特异性不足够用于筛选或微小残留癌的检测， 但它还是有用的， 由於检测的低费用和还是可能预示治疗的成效。 例如，预示采用细胞毒素药物或是内分泌物治疗无效患者， 停止用药物， 将大大降低治疗费用);S-TK1 is one promising candidate but information have to be collected in prospective ongoing clinical trials (S-TK1 是可信赖的候选者之一， 但需要进一步进行临床试用).